GRN and MAPT Mutations in 2 Frontotemporal Dementia Research Centers in Brazil.

Alzheimer Dis Assoc Disord

*Cognitive and Behavioral Neurology Unit, Department of Neurology, Hospital das Clinicas, University of Sao Paulo (USP) Medical School ‡Department of Neurology, Neuroregeneration Center (LIM 45) ∥Department of Pathology §Discipline of Pathophysiology, University of Sao Paulo Medical School, Sao Paulo †Cognitive and Behavioral Neurology Unit, Department of Internal Medicine, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil ¶Department of Neurology, University of California, San Francisco, CA.

Published: November 2017

AI Article Synopsis

  • The study focused on the prevalence of GRN and MAPT mutations in frontotemporal dementia (FTD) patients from two Brazilian research centers.
  • Researchers analyzed 76 individuals with different forms of FTD, finding GRN mutations in 9.6% and MAPT mutations in 7.1% of the cases.
  • The findings include three novel GRN mutations and suggest that GRN mutations are more common in familial cases of FTD, highlighting the need for further research in Latin America.

Article Abstract

Background: Mutations in GRN (progranulin) and MAPT (microtubule-associated protein tau) are among the most frequent causes of monogenic frontotemporal dementia (FTD), but data on the frequency of these mutations in regions such as Latin America are still lacking.

Objective: We aimed to investigate the frequencies of GRN and MAPT mutations in FTD cohorts from 2 Brazilian dementia research centers, the University of Sao Paulo and the Federal University of Minas Gerais medical schools.

Methods: We included 76 probands diagnosed with behavioral-variant FTD (n=55), semantic-variant Primary Progressive Aphasia (PPA) (n=11), or nonfluent-variant PPA (n=10). Twenty-five percent of the cohort had at least 1 relative affected with FTD.

Results: Mutations in GRN were identified in 7 probands, and in MAPT, in 2 probands. We identified 3 novel GRN mutations (p.Q130X, p.317Afs*12, and p.K259Afs*23) in patients diagnosed with nonfluent-variant PPA or behavioral-variant FTD. Plasma progranulin levels were measured and a cutoff value of 70 ng/mL was found, with 100% sensitivity and specificity to detect null GRN mutations.

Conclusions: The frequency of GRN mutations was 9.6% and that of MAPT mutations was 7.1%. Among familial cases of FTD, the frequency of GRN mutations was 31.5% and that of MAPT mutations was 10.5%.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065374PMC
http://dx.doi.org/10.1097/WAD.0000000000000153DOI Listing

Publication Analysis

Top Keywords

mapt mutations
16
grn mutations
12
mutations
10
grn
8
grn mapt
8
frontotemporal dementia
8
dementia centers
8
mutations grn
8
behavioral-variant ftd
8
nonfluent-variant ppa
8

Similar Publications

The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate 'pro-aging' or 'pro-youthful' effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear.

View Article and Find Full Text PDF

Introduction: Tau protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and in regulating neuronal excitability. Among tau-coding microtubule associated protein tau () gene mutations, the A152T mutation is reported to increase the risk of AD and neuronal excitability in mouse models.

Methods: To investigate the effects of gene expression and its mutations on neuronal activity in human neurons, we employed genome editing technology to introduce the A152T or P301S mutations into induced pluripotent stem cells (iPSCs).

View Article and Find Full Text PDF

L266V Gene Mutation Associated With Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Syndrome.

J Neuropsychiatry Clin Neurosci

January 2025

Departments of Psychiatry (Rivas-Grajales) and Neurology (Han, Wang), Boston University Chobanian & Avedisian School of Medicine, Boston; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (Greenstein, Shih).

View Article and Find Full Text PDF

Frontotemporal dementia with parkinsonism-17 is a neurodegenerative disease characterised by pathological aggregation of the tau protein with the formation of neurofibrillary tangles and subsequent neuronal death. The inherited form of frontotemporal dementia can be caused by mutations in several genes, including the MAPT gene on chromosome 17, which encodes the tau protein. As there are currently no medically approved treatments for frontotemporal dementia, there is an urgent need for research using in vitro cell models to understand the molecular genetic mechanisms that lead to the development of the disease, to identify targets for therapeutic intervention and to test potential drugs to prevent neuronal death.

View Article and Find Full Text PDF

Tau pathology is a hallmark of several neurodegenerative diseases, including frontotemporal dementia and Alzheimer's disease. However, the sequence of events and the form of tau that confers toxicity are still unclear, due in large part to the lack of physiological models of tauopathy initiation and progression in which to test hypotheses. We have developed a series of targeted mice expressing frontotemporal-dementia-causing mutations in the humanized MAPT gene to investigate the earliest stages of tauopathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!